SAB Biotherapeutics, Inc. (SABS)
3.71
-0.08
(-2.11%)
USD |
NASDAQ |
Aug 31, 16:00
3.715
0.00 (0.00%)
After-Hours: 20:00
SAB Biotherapeutics Total Assets (Quarterly) : 238.21M for June 30, 2026
Total Assets (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Total Assets (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 238.21M |
| March 31, 2026 | 248.47M |
| December 31, 2025 | 174.52M |
| September 30, 2025 | 183.45M |
| June 30, 2025 | 30.13M |
| March 31, 2025 | 38.12M |
| December 31, 2024 | 46.06M |
| September 30, 2024 | 53.80M |
| June 30, 2024 | 61.89M |
| March 31, 2024 | 71.37M |
| December 31, 2023 | 83.94M |
| September 30, 2023 | 28.34M |
| Date | Value |
|---|---|
| June 30, 2023 | 35.44M |
| March 31, 2023 | 42.67M |
| December 31, 2022 | 50.90M |
| September 30, 2022 | 52.51M |
| June 30, 2022 | 59.15M |
| March 31, 2022 | 67.47M |
| December 31, 2021 | 81.14M |
| September 30, 2021 | 116.93M |
| June 30, 2021 | 117.09M |
| March 31, 2021 | 117.27M |
| December 31, 2020 | 0.3222M |
Total Assets Definition
Assets are a main portion of the balance sheet of a company that measure things that provide economic value. A few examples of assets of a company include cash, inventories, and accounts receivable. From an accounting perspective, the balance sheet equation is Assets = Liabilities + Shareholder's Equity.
Total Assets (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Total Assets (Quarterly) Benchmarks
| Arrowhead Pharmaceuticals, Inc. | 2.112B |
| Oncolytics Biotech, Inc. | 7.671M |
| Sangamo Therapeutics, Inc. | 59.96M |
| Sarepta Therapeutics, Inc. | 3.189B |
| Anixa Biosciences, Inc. | 14.86M |
Total Assets (Quarterly) Related Metrics
| Total Liabilities (Quarterly) | 23.42M |
| Shareholders Equity (Quarterly) | 214.78M |
| Debt to Equity Ratio | 0.0239 |
| Current Ratio | 9.221 |
| Net Debt Paydown Yield | 0.10% |